Pregnancy-Associated Plasma Protein A and Alpha-fetoprotein and Prediction of Adverse Perinatal Outcome

OBJECTIVE: To describe the association between pregnancy associated plasma protein A (PAPP-A), alpha-fetoprotein (AFP) and adverse perinatal outcome. METHODS: We conducted a multicenter prospective cohort study of 8,483 women attending for prenatal care in southern Scotland between 1998 and 2000. The risk of delivering a small for gestational age infant, delivering preterm, and stillbirth were related to maternal serum levels of PAPP-A and AFP. RESULTS: Women with a low PAPP-A were not more likely to have elevated levels of AFP. Compared with women with a normal PAPP-A and a normal AFP, the odds ratio for delivering a small for gestational age infant for women with a high AFP was 0.9 (95% confidence interval [CI] 0.5–1.6), for women with a low PAPP-A was 2.8 (95% CI 2.0–4.0), and for women with both a high AFP and a low PAPP-A was 8.5 (95% CI 3.6–20.0). The odds ratio for delivering preterm for women with a high AFP was 1.8 (95% CI 1.3–2.7), for women with a low PAPP-A was 1.9 (95% CI 1.3–2.7), and for women with both a low PAPP-A and a high AFP was 9.9 (95% CI 4.4–22.0). These interactions were statistically significant for both outcomes (P = .03 and .04, respectively). There was a nonsignificant trend toward a similar interaction in relation to stillbirth risk. Of the women with the combination of a low PAPP-A and high AFP, 32.1% (95% CI 15.9–52.4) delivered a low birth weight infant. CONCLUSION: Low maternal serum levels of PAPP-A between 10 and 14 weeks and high levels of AFP between 15 and 21 weeks gestation are synergistically associated with adverse perinatal outcome. LEVEL OF EVIDENCE: II-2

[1]  Z Alfirevic,et al.  Doppler ultrasound for fetal assessment in high risk pregnancies , 2010 .

[2]  Jill P Pell,et al.  First-trimester placentation and the risk of antepartum stillbirth. , 2004, JAMA.

[3]  F. Malone,et al.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). , 2004, American journal of obstetrics and gynecology.

[4]  E. Thom,et al.  Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. , 2004, American journal of obstetrics and gynecology.

[5]  J. Pell,et al.  Second-trimester maternal serum levels of alpha-fetoprotein and the subsequent risk of sudden infant death syndrome. , 2004, The New England journal of medicine.

[6]  E. Füchtbauer,et al.  Metalloproteinase pregnancy-associated plasma protein A is a critical growth regulatory factor during fetal development , 2004, Development.

[7]  J. Connor,et al.  Combined ultrasound and biochemical screening for Down's Syndrome in the first trimester: a Scottish multicentre study , 2002, BJOG : an international journal of obstetrics and gynaecology.

[8]  Gordon C. S. Smith,et al.  Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. , 2002, The Journal of clinical endocrinology and metabolism.

[9]  L. Giudice,et al.  Pregnancy‐associated plasma protein‐A (PAPP‐A) cleaves insulin‐like growth factor binding protein (IGFBP)‐5 independent of IGF: implications for the mechanism of IGFBP‐4 proteolysis by PAPP‐A , 2001, FEBS letters.

[10]  C. J. Colby,et al.  Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy. , 1999, The New England journal of medicine.

[11]  L. Giudice,et al.  Role of the IGF system in trophoblast invasion and pre-eclampsia. , 1999, Human reproduction.

[12]  J. Haddow,et al.  REFINEMENTS IN MANAGING MATERNAL WEIGHT ADJUSTMENT FOR INTERPRETING PRENATAL SCREENING RESULTS , 1996, Prenatal diagnosis.

[13]  P. McLoone,et al.  Deprivation and mortality in Scotland, 1981 and 1991 , 1994, BMJ.

[14]  A. Smith,et al.  Alpha‐Fetoprotein: A Biomarker for Pregnancy Outcome , 1993, Epidemiology.

[15]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .